Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
(→Pharmacy and chemistry: rfz) |
m (→Mild inducers) |
||
(24 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in | [[File:1Eslicarbazepine acetate structure.svg.png|thumb]] | ||
S-licarbazepine is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic [[epilepsy]] of infancy<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501557/pdf/main.pdf Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases]</ref><ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12894/epdf Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial]</ref> | |||
==Pharmacy and chemistry== | ==Pharmacy and chemistry== | ||
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix TM) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | ||
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to [[carbazepine]]; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | ||
==Pharmacology== | |||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action] | |||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330027/ Clinical utility of eslicarbazepine: current evidence] | |||
===Mild inducers=== | |||
After de Leon the following AED groups as mild inducers: | |||
*clobazam | |||
*eslicarbazepine | |||
*[[rufinamide]] | |||
*felbamate | |||
*[[lamotrigine]] | |||
*[[oxcarbazepine]] | |||
*[[topiramate]] | |||
*vigabatrin | |||
*[[valproic acid|VPA]] | |||
<ref>[http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90431353&pident_usuario=0&pcontactid=&pident_revista=486&ty=55&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=en&fichero=486v08n02a90431353pdf001.pdf The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians ]</ref> | |||
===Cutaneous adverse effects=== | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231563/ Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine] | |||
==ATC code N03== | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
: [[wikipedia:eslicarbazepine|eslicarbazepine]] | |||
<ref>http://www.whocc.no/atc_ddd_index/?code=N03AF04</ref></center> | |||
|} | |||
{{Wikidata|Q410273}} | |||
==Bioequivalence== | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689905/pdf/40268_2013_Article_16.pdf Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects] | |||
==References== | |||
<references/> | <references/> | ||
[[Category:Anticonvulsants]] |
Latest revision as of 19:17, 13 October 2017
S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]
Pharmacology
- Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
- Clinical utility of eslicarbazepine: current evidence
Mild inducers
After de Leon the following AED groups as mild inducers:
- clobazam
- eslicarbazepine
- rufinamide
- felbamate
- lamotrigine
- oxcarbazepine
- topiramate
- vigabatrin
- VPA
Cutaneous adverse effects
Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine
ATC code N03
Bioequivalence
References
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT
- ↑ The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AF04